Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | EIF4E | P06730 | 10/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | DDX3X | O00571 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1847303 | 0.78 | ESR2 (0.58) | ESR2ALDH1A1TDP1LMNAMAPT | |
| SCHEMBL27851500 | 0.76 | TDP1 (0.50) | ESR2ALDH1A1TDP1EIF4EMGAM | |
| SCHEMBL30535903 | 0.75 | ALDH1A1 (0.74) | ALDH1A1TDP1MGAMGAASI | |
| SCHEMBL1287837 | 0.75 | ALDH1A1 (0.74) | ALDH1A1TDP1MGAMGAASI | |
| SCHEMBL4439669 | 0.75 | TSHR (0.59) | ALDH1A1TDP1EIF4ELMNAMAPT | |
| SCHEMBL7821791 | 0.75 | ESR2 (1.00) | ESR2ALDH1A1TDP1MAPTHTT | |
| SCHEMBL31540411 | 0.73 | BCAT2 (0.46) | ESR2ALDH1A1LMNA | |
| SCHEMBL4134237 | 0.73 | RORB (0.51) | ALDH1A1GAA | |
| SCHEMBL31540417 | 0.73 | BCAT2 (0.46) | LMNAMAPTMGAMGAASI | |
| SCHEMBL29120749 | 0.73 | MAPT (0.57) | ALDH1A1TDP1EIF4ELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237617-A1 | THIENO[2,3-C] ISOQUINOLINES FOR USE AS INHIBITORS OF PARP | PELLICCIARI ROBERTO | 2011-09-29 | — | — | US | disclosed |
| US-20110237617-A1 | THIENO[2,3-C] ISOQUINOLINES FOR USE AS INHIBITORS OF PARP | PELLICCIARI ROBERTO | 2011-09-29 | — | — | US | disclosed |
| US-20110237617-A1 | THIENO[2,3-C] ISOQUINOLINES FOR USE AS INHIBITORS OF PARP | PELLICCIARI ROBERTO | 2011-09-29 | — | — | US | disclosed |
| US-7825129-B2 | Thieno[2,3-c] isoquinolines for use as inhibitors of PARP | PELLICCIARI ROBERTO | 2010-11-02 | — | — | US | disclosed |
| US-7825129-B2 | Thieno[2,3-c] isoquinolines for use as inhibitors of PARP | PELLICCIARI ROBERTO | 2010-11-02 | — | — | US | disclosed |
| US-7825129-B2 | Thieno[2,3-c] isoquinolines for use as inhibitors of PARP | PELLICCIARI ROBERTO | 2010-11-02 | — | — | US | disclosed |
| EP-1464646-B1 | Thieno(2,3-C) Isoquinolines for use as inhibitors of Parp | PELLICCIARI ROBERTO (IT) | 2009-09-30 | — | — | EP | disclosed |
| US-20060094746-A1 | Thieno[2,3-c] isoquinolines for use as inhibitors of PARP | PELLICCIARI ROBERTO | 2006-05-04 | — | — | US | disclosed |
| US-6989388-B2 | Thieno[2,3-c]iosquinolines for use as inhibitors of PARP | Pellicciari, Roberto (IT) | 2006-01-24 | — | — | US | disclosed |
| EP-1464646-A1 | Thieno(2,3-C) Isoquinolines for use as inhibitors of Parp | SMITHKLINE BEECHAM PLC (GB) | 2004-10-06 | — | — | EP | disclosed |
| US-20040082789-A1 | Thieno[2,3-c]iosquinolines for use as inhibitors of parp | MORONI, FLAVIO (IT) | 2004-04-29 | — | — | US | disclosed |
| EP-1332147-A1 | THIENO[2,3-C ISOQUINOLINES FOR USE AS INHIBITORS OF PARP | SMITHKLINE BEECHAM PLC (GB) | 2003-08-06 | — | — | EP | disclosed |
| WO-2002036599-A1 | THIENO[2,3-C]ISOQUINOLINES FOR USE AS INHIBITORS OF PARP | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237617-A1 | THIENO[2,3-C] ISOQUINOLINES FOR USE AS INHIBITORS OF PARP | PARP1, PARP2, PARP3 | ESR2 1535/4885ALDH1A1 136/4885TDP1 42/4885 |
| US-20040082789-A1 | Thieno[2,3-c]iosquinolines for use as inhibitors of parp | PARP1, PARP2, PARP12 | ESR2 2179/4885ALDH1A1 1365/4885TDP1 53/4885 |
| US-20060094746-A1 | Thieno[2,3-c] isoquinolines for use as inhibitors of PARP | PARP1, PARP2, PARP3 | ESR2 1535/4885ALDH1A1 136/4885TDP1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.